Roger L. Shapiro

Dr. Shapiro is an Associate Professor in Medicine at Harvard Medical School and the Harvard TH Chan School of Public Health. His primary research interests are in the prevention of mother-to-child HIV transmission (PMTCT) and the reduction of morbidity and mortality among infants born to HIV-infected women. Since 1999, Dr. Shapiro has studied infant outcomes and PMTCT strategies in several large NIH-funded clinical trials in Botswana. He was a co-investigator of the Mashi Study, which evaluated several PMTCT interventions among 1200 mother-infant pairs; the principal investigator of the Mma Bana Study, which compared 3 different antiretroviral combinations during pregnancy, delivery, and breastfeeding among 730 mothers-infant pairs; co-principal investigator of the Mpepu Study, which evaluated strategies for reduce infant mortality among over 3,000 HIV-exposed uninfected infants; and principal investigator for several studies of adverse birth outcomes. He is currently the principal investigator for NIH-funded studies that perform nationwide surveillance studies to evaluate the mechanisms by which antiretrovirals impact adverse birth outcomes; an ongoing clinical trial of early antiretroviral treatment to improve clinical outcomes in HIV-infected infants (the Early Infant Treatment Study); and novel use of broadly neutralizing monoclonal antibodies as alternate treatment for early-treated, low-reservoir children. Dr. Shapiro works closely with the Botswana PMTCT Program, and is a member of the PMTCT Advisory Panel for the World Health Organization.